An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
An Open Label Two-stage Study of Orally Administered BKM120 in Patients With Metastatic Non-small Cell Lung Cancer With Activated PI3K Pathway
The purpose of this two-stage phase II study is to assess the efficacy of BKM120, as measured by determining the progression free survival (PFS), in patients with pretreated metastatic Non-small Cell Lung Cancer (NSCLC) that exhibits PI3K pathway activation. BKM120 will be investigated in two groups of NSCLC patients according to the histology of the cancer: squamous and non-squamous.
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Los Angeles, California 90048, United States
San Diego, California 92103, United States
Greenwood Village, Colorado 80218, United States
Atlanta, Georgia 30322, United States
Worcester, Massachusetts 01608, United States
St Louis, Missouri 63110, United States
Morristown, New Jersey 07962, United States
Summit, New Jersey 07901, United States
Oklahoma City, Oklahoma 73104, United States
Dallas, Texas 75246, United States
Dallas, Texas 75390-9151, United States
*see Various Departments*, Virginia 23502, United States
Buenos Aires, Buenos Aires C1050AAK, Argentina
Rio Negro, Viedma 8500, Argentina
Koto, Tokyo 135-8550, Japan